Radius Health Historical Chart
[ Nasdaq ]
|Priced at $8.00
||$8.03||6.5 million||6/6/2014 |
Underwriter(s): Jefferies, Cowen & Co.
Co-Manager(s): Canaccord Genuity, Cantor Fitzgerald & Co.
Terms Added 2014-04-25
Terms Added 2014-06-02
For IPO Boutique's "scale of 1 to 5" BUY rating on Radius Health, and our comprehensive analysis, click the "Buy Market Research" link.
- Click chart for current quote
About Radius Health (adapted from Radius Health prospectus):
Share this IPO Profile:
Radius Health is a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions. Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, which can lead to an increase in fractures. Their lead product candidate is BA058, a novel synthetic peptide analog of human parathyroid hormone-related protein, or hPTHrP, a naturally-occurring bone building hormone.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "RDUS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2017 IPO Boutique. All Rights Reserved